Top Adderall XR Brands to Consider for Optimal Focus

In recent years, the demand for effective treatments for attention deficit hyperactivity disorder (ADHD) has led to the rise of several reputable brands offering Adderall XR, a popular extended-release medication. Among these brands, some have gained prominence due to their commitment to quality and patient satisfaction. As patients and healthcare providers seek reliable options, understanding which brands stand out can make a significant difference in managing ADHD symptoms effectively. To explore a comprehensive list of the best brands for Adderall XR, continue reading below.

Illustration of adderall xr

Best brands of adderall xr in 2025

Shire Pharmaceuticals

Shire Pharmaceuticals, now a subsidiary of Takeda, was a key producer of Adderall XR, an extended-release medication for ADHD, initially launched in 2002 and holding a market share of 23.8% in 2003. Sales of Adderall XR rose 21% to $111 million in Q1 2011 despite facing generic competition. Even though Shire encountered manufacturing limits imposed by the DEA, they maintained a significant portion of the market through both branded and authorized generic sales until 2019, when they were acquired by Takeda. The medication's formula uses a mix of amphetamine salts designed for extended release over 10-12 hours, and Shire made various dosage strengths, including 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg.

Teva Pharmaceuticals

Teva Pharmaceuticals, a leading global pharmaceutical company, is a prominent producer of generic Adderall XR, having received FDA approval for their version in 2013, and at one point held around 30% market share for their copycat versions; their generic version offers a more affordable alternative to the brand-name medication, using the same active ingredients of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate. Teva's generic Adderall XR is considered therapeutically equivalent and substitutable for prescriptions written for brand-name Adderall XR; this extended-release medication is used to treat attention deficit hyperactivity disorder (ADHD) by increasing attention and decreasing impulsiveness and hyperactivity. For detailed insights, visit Teva's website.

Sandoz

Sandoz, a division of Novartis, is a notable producer of generic Adderall XR, distributing it in the U.S. since 2016 through an agreement with Shire, who manufactures the drug. While they don't produce it, Sandoz has an exclusive agreement to sell this generic version for five years starting in 2013, receiving a supply of all dosage strengths from Shire. Even though in 2022 they experienced backorders on the 15mg and 20mg dosages, they remain a key player in the market, and it's important to note that the agreement was to sell the authorized generic version of Adderall XR.

Actavis

Actavis, now a part of Allergan following a $66 billion acquisition in 2015, became a significant producer of generic Adderall XR, having received FDA approval for its version in 2012. This move contributed to the approximately $1.99 billion market of Adderall XR and its equivalents that year, intensifying market competition. While Actavis was a key player, other companies like Teva and Impax also produced authorized generic versions of Adderall XR, with Shire being the original manufacturer of the brand-name drug. Actavis's entry into the market provided more supply options to patients, particularly during shortages in 2012. However, in 2016, Allergan, previously Actavis, recalled nearly 600,000 bottles of their generic Adderall due to impurity issues. For information about the branded medication, you can visit the Adderall XR website.

Global Pharmaceuticals

Global Pharmaceuticals, a division of Impax Laboratories, positioned itself as a key player in the Adderall XR market, particularly after 2009 when they began shipping their authorized generic version, with sales reaching $516 million by 2012. This established them as a major generic supplier of the drug, and although facing competition, they maintained a significant presence by offering a lower-cost alternative. In 2016, they received FDA approval for their own generic version of Adderall XR, and by 2015, the combined brand and generic sales of the drug reached $1.8 billion in the US.

Barr Pharmaceuticals

Barr Pharmaceuticals, now a subsidiary of Teva, was a significant player in the generic Adderall XR market, having reached a settlement with Shire in 2006 which allowed them to launch their generic version on April 1, 2009, with an exclusive 180-day marketing period. Although Barr admitted that their product infringed on one of Shire's patents, this agreement enabled a pro-competitive market entry for a generic version of Adderall XR much earlier than would have been possible. Teva continues to sell a generic version of Adderall XR under the 2006 license and distribution agreement with Shire. Despite challenges and litigation, Barr's entry into the market provided consumers with more affordable options for this medication, and in 2012, the total annual sales of both brand and generic Adderall XR in the US were around $2 billion. You can find more information about Adderall XR on the official website.

Aurobindo Pharma

Aurobindo Pharma, established in 1986, is a significant pharmaceutical company with a strong presence in the US market, where it generates 48% of its revenue. While they produce a range of medications, including a generic version of Adderall XR, it is important to note that in 2019, Aurobindo USA recalled over 11,000 bottles of mixed amphetamine salts due to super potency concerns. Although the company has a large portfolio of products, the generic market for Adderall XR is competitive with several manufacturers and has experienced supply issues recently. The company has faced several product recalls over the years, and the market for amphetamine mixed salts, the active ingredient in Adderall XR, is estimated to be around $1.56 billion annually.

Lannett Company

Lannett Company, a significant player in generic pharmaceuticals, began marketing its generic version of Adderall XR in 2020, with strengths of 5mg to 30mg, capturing a portion of the estimated $1.3 billion market, and continues to distribute it, despite ongoing industry-wide shortages, through a strategic partnership with Elite Pharmaceuticals, who manufactures it. The company's generic Adderall XR product is available in the US market, with a specific NDC number (00527-0790-37) and is manufactured in Seymour, IN. Although there are other generic suppliers, Lannett aims to provide affordable medicines for ADHD. For more information about their generic Adderall XR product, visit their official website.

Novartis

While Novartis doesn't directly produce Adderall XR, their generic division Sandoz, entered into an agreement with Shire in 2013 to exclusively sell an authorized generic version of Adderall XR, supplied by Shire, starting in 2016. Although Sandoz has experienced some supply issues with 15-mg and 20-mg doses in 2022, Takeda Pharmaceuticals is currently the market authorization holder for Adderall XR in Canada, and in the U.S. Teva Pharmaceuticals also manufactures a generic version, and Elite Pharmaceuticals began shipping their generic version in 2023. For more information about Adderall XR, you can visit the Takeda Pharmaceuticals website.

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals is a significant producer of generic Adderall XR, containing amphetamine and dextroamphetamine salts, and while they do not hold the original brand patent, their version is a widely available option; in 2003, Adderall XR held almost 25% of the ADHD drug market share, demonstrating its initial impact, and today, Mallinckrodt continues to manufacture and distribute this medication in various dosages. It's important to note that in 2022, there was a shortage of the immediate-release version of amphetamine mixed salts, but the extended-release version, like Mallinckrodt's generic Adderall XR, remained available. For more information about the product, you can visit their website.